Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Stock Market

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ABEO

HIBB

JBLU

OPRT

PALI

Crude Oil Moves Higher; General Motors Earnings Top Views

Movers

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HRTX

HSTM

JAGX

KULR

LICN

MESO

MLEC

MSCI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

TTOO

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Dow Jumps Over 200 Points; US Services PMI Falls In April

Abeona Therapeutics Inc

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 57.5 percent. This is a 31.25 percent decrease over losses of $(0.48) per share from the same period last year.

Earnings

Earnings Misses

Abeona Therapeutics Q3 2024 GAAP EPS $(0.63) Misses $(0.40) Estimate

Abeona Therapeutics Announces FDA Acceptance Of BLA Resubmission For Pz-cel In Recessive Dystrophic Epidermolysis Bullosa

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and maintains $18 price target.

Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target

Biotech

Health Care

General

Abeona Therapeutics Has Resubmitted Its Biologics License Application To The FDA For Prademagene Zamikeracel (Pz-cel), Its Investigational Autologous Cell-based Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysis of inpatient hospital procedures using pz-cel. The code will go into effect on October 1, 2024.

The Centers For Medicare And Medicaid Services Has Granted A Product-specific Procedure Code Icd-10-PCS For Abeona Therapeutics' Prademagene Zamikeracel (Pz-cel), Investigational Autologous Cell-based Gene Therapy Currently In Development For Recessive Dystrophic Epidermolysis Bullosa

WIIM

Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

Earnings Beats

Abeona Therapeutics Q2 EPS $(0.26) Beats $(0.36) Estimate, Cash Balance $123M

Abeona Therapeutics Concludes Type A Meeting With FDA To Align On Upcoming Pz-cel BLA Resubmission, Continues To Expect To Resubmit BLA In Second Half Of 2024

Under the terms of the agreement, Beacon will have the right to evaluate, for a 12-month period, the AAV204 capsid for potential use in certain ophthalmology indications, with an option to take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. Under the agreement, Abeona will receive an upfront payment upon Beacon&#39;s exercise of its option to license AAV204, with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204. Beacon will be responsible for the development and commercialization of all licensed products. The targets for which Beacon would receive rights under its non-exclusive license agreement are distinct from those currently in development at Abeona.

Contracts

Abeona Therapeutics And Beacon Therapeutics Announced An Agreement By Which Beacon Will Evaluate Abeona's Patented AAV204 Capsid For The Development And Commercialization Of Potential Gene Therapies For Select Ophthalmology Indications

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $15.

Initiation

HC Wainwright & Co. Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $15

<h3>Gainers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 12.83% to $0.33. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock increased by 5.73% to $1.66. The company's market cap stands at $164.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) stock fell 7.8% to $179.0 during Thursday's after-market session. The company's market cap stands at $28.9 billion. The company's, Q1 earnings came out today. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares fell 6.64% to $2.23. The company's market cap stands at $6.9 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 6.6% to $0.23. The market value of their outstanding shares is at $5.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 6.14% to $2.45. The company's market cap stands at $58.4 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock fell 5.0% to $0.66. The market value of their outstanding shares is at $11.0 million. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) stock fell 4.99% to $4.0. The company's market cap stands at $164.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

ARAY

COSM

CPHI

Intelligent Bio Solutions Inc. - Common Stock

INBS

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

ONMD

PHGE

RSLS

VEEV

VIRI

12 Health Care Stocks Moving In Thursday's After-Market Session

Stifel analyst Dae Gon Ha initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $21.

Stifel Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $21

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and lowers the price target from $28 to $21.

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21

Abeona Therapeutics shares are trading higher. The company reported Q1 financial results.

Press Releases

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Abeona Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga